Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Cardiovascular fitness is the foundation of endurance, stamina, and heart health. When your cardiovascular system is in top shape, everything feels more manageable, whether you're chasing your kids ...